Disc Medicine Stock (NASDAQ:IRON)

Forecast Ownership Financials Chart

Previous Close

$75.86

52W Range

$40.00 - $99.50

50D Avg

$71.64

200D Avg

$74.63

Market Cap

$2.83B

Avg Vol (3M)

$570.65K

Beta

2.07

Div Yield

IRON Company Profile

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

155

IPO Date

Aug 12, 2020

Website

IRON Performance

IRON Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-236.02M	$-129.72M	$-91.13M
Net Income	$-212.18M	$-109.36M	$-76.43M
EBITDA	$-236.02M	$-108.27M	$-76.23M
Basic EPS	$-6.01	$-3.96	$-3.42
Diluted EPS	$-6.01	$-3.96	$-3.42

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
AAPG	Ascentage Pharma Group International
ADPT	Adaptive Biotechnologies Corporation
TARS	Tarsus Pharmaceuticals, Inc.
CELC	Celcuity Inc.
CGON	CG Oncology Inc.
XENE	Xenon Pharmaceuticals Inc.
ZLAB	Zai Lab Limited
LEGN	Legend Biotech Corporation
SRRK	Scholar Rock Holding Corporation
APGE	Apogee Therapeutics, Inc.